In 2021, the global acute kidney injury treatment market is predicted to be worth US$ 1,857.8 million, with a CAGR of 7.2 percent during the forecast period (2021-2028).

 

Acute kidney Injury Treatment Market

When the kidneys stop filtering waste items from the blood, this is known as acute kidney damage.

Body fluids, electrolytes, and acid-base balance are all affected by kidney failure.

Prerenal, postrenal, and intrinsic failures can contribute to acute kidney damage.

Hemodialysis and continuous renal replacement therapy may be used depending on the degree of the injury.

The goal of treatment is to improve kidney function rather than cure the kidney.

During the forecast period, the market is expected to develop due to an increase in the frequency of acute renal injuries.

Over the projected period, the worldwide acute renal injury treatment market is expected to develop due to an increase in the frequency of acute kidney injuries.

According to the International Society of Nephrology, acute kidney damage affects roughly 13.3 million people worldwide each year.

Acute renal damage is also responsible for 1.7 million deaths worldwide each year.

During the forecast period, increasing technological improvements are expected to boost the market growth.

The development of treatments for the acute kidney injury treatment market is likely to fuel the worldwide acute kidney injury treatment market growth during the forecast period, according to key players in the market.

Key Players

Quark Pharmaceuticals, Inc., Baxter International, Inc., Novartis AG., B. Braun Melsungen AG, Fresenius Medical Care, Medtronic, Astellas Pharma Inc.